Second primary acute lymphoblastic leukemia in adults: A SEER analysis of incidence and outcomes

Abhisek Swaika, Ryan D. Frank, Dongyun Yang, Laura E. Finn, Liuyan Jiang, Pooja Advani, Asher A Chanan Khan, Sikander Ailawadhi, James M Foran

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15 months; HR 1.20, 95% CI 1.10-1.31, P < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95% CI 1.58-1.95, P < 0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epidemiology
Incidence
Survival
Prostate
Neoplasms
Breast
Demography

Keywords

  • Second primary acute lymphoblastic leukemia
  • Second primary ALL
  • SEER analysis
  • SIRs
  • Standardized incidence ratios

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Second primary acute lymphoblastic leukemia in adults : A SEER analysis of incidence and outcomes. / Swaika, Abhisek; Frank, Ryan D.; Yang, Dongyun; Finn, Laura E.; Jiang, Liuyan; Advani, Pooja; Chanan Khan, Asher A; Ailawadhi, Sikander; Foran, James M.

In: Cancer Medicine, 01.01.2017.

Research output: Contribution to journalArticle

@article{1acc71b428f049ec9647dc5c4f3f2b79,
title = "Second primary acute lymphoblastic leukemia in adults: A SEER analysis of incidence and outcomes",
abstract = "We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1{\%} vs. 42.9{\%}), white patients (72.0{\%} vs. 59.5{\%}), older patients (58.8{\%} vs. 25.2{\%}; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8{\%} vs. 53.9{\%}) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15 months; HR 1.20, 95{\%} CI 1.10-1.31, P < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9{\%}) and prostate (17.4{\%}). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95{\%} CI 1.58-1.95, P < 0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.",
keywords = "Second primary acute lymphoblastic leukemia, Second primary ALL, SEER analysis, SIRs, Standardized incidence ratios",
author = "Abhisek Swaika and Frank, {Ryan D.} and Dongyun Yang and Finn, {Laura E.} and Liuyan Jiang and Pooja Advani and {Chanan Khan}, {Asher A} and Sikander Ailawadhi and Foran, {James M}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cam4.1266",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Second primary acute lymphoblastic leukemia in adults

T2 - A SEER analysis of incidence and outcomes

AU - Swaika, Abhisek

AU - Frank, Ryan D.

AU - Yang, Dongyun

AU - Finn, Laura E.

AU - Jiang, Liuyan

AU - Advani, Pooja

AU - Chanan Khan, Asher A

AU - Ailawadhi, Sikander

AU - Foran, James M

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15 months; HR 1.20, 95% CI 1.10-1.31, P < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95% CI 1.58-1.95, P < 0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.

AB - We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15 months; HR 1.20, 95% CI 1.10-1.31, P < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95% CI 1.58-1.95, P < 0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.

KW - Second primary acute lymphoblastic leukemia

KW - Second primary ALL

KW - SEER analysis

KW - SIRs

KW - Standardized incidence ratios

UR - http://www.scopus.com/inward/record.url?scp=85039146866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039146866&partnerID=8YFLogxK

U2 - 10.1002/cam4.1266

DO - 10.1002/cam4.1266

M3 - Article

C2 - 29282894

AN - SCOPUS:85039146866

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -